Novavax INC Form 4 insider transactions

EVP and Chief Legal Officer of Novavax, Mark J. Casey, reports the acquisition of stock options and restricted stock units (RSUs) in the company.

Draghia-Akli Ruxandra, a Novavax officer, reports the acquisition of stock options and restricted stock units (RSUs) in a recent SEC Form 4 filing.

Novavax CEO John Jacobs was granted stock options for 676,000 shares and 450,500 restricted stock units (RSUs) on March 3, 2025, according to a Form 4 filing.

Elaine O'Hara, EVP and Chief Strategy Officer of Novavax, reports the acquisition of stock options and restricted stock units.

EVP, CFO, and Treasurer of Novavax, James Patrick Kelly, reports the acquisition of stock options and restricted stock units.

John Trizzino, President and COO of Novavax, reports the disposition of shares related to the vesting of restricted stock units.

EVP and Chief Legal Officer of Novavax, Mark J. Casey, reports the vesting and disposal of restricted stock units and common stock.

EVP, CFO, and Treasurer of Novavax, James Patrick Kelly, reports the disposition of common stock and restricted stock units on March 1, 2025.

Novavax CEO John Jacobs reports the disposition of shares to cover tax obligations upon vesting of restricted stock units.

Elaine O'Hara, EVP and Chief Strategy Officer of Novavax, reports the acquisition and disposal of common stock and restricted stock units on March 1, 2025.

Director Gregg H. Alton reports multiple transactions involving Novavax Inc. common stock throughout 2024, resulting in an increased direct ownership.

Director Margaret McGlynn reports acquisition of Novavax common stock through multiple transactions.

Novavax CEO John C. Jacobs reports the acquisition of 83,196 shares of common stock through the vesting of restricted stock units and the disposal of 38,873 shares to cover tax obligations.

EVP, CFO and Treasurer of Novavax, James Patrick Kelly, reports the acquisition and disposal of Novavax common stock on December 31, 2024.

Director Richard J. Rodgers reports a transaction involving Novavax Inc. common stock and Restricted Stock Units (RSUs) on October 29, 2024.

Director Rachel K. King sold 4,150 shares of Novavax Inc. (NVAX) on December 13, 2024, at a price of $9.0205 per share.

Director James F. Young sold a total of 10,000 Novavax shares in December 2024.

A Novavax executive, Mark J. Casey, exercised stock options and sold shares on December 11, 2024, resulting in a change in his beneficial ownership.

Novavax officer Ruxandra Draghia-Akli was granted stock options and restricted stock units, according to a recent SEC filing.

EVP, CCO, and CBO of Novavax, John Trizzino, reports the acquisition and disposal of common stock and restricted stock units.

EVP, CFO, and Treasurer of Novavax, James Patrick Kelly, reports the acquisition and disposal of common stock and restricted stock units on August 16, 2024.

Director James F. Young sold 7,500 shares of Novavax Inc. at $14.09 per share on June 21, 2024.

Director James F. Young of Novavax Inc. (NVAX) recently sold a portion of his holdings in two separate transactions on June 18, 2024.

Filip Dubovsky, President of R&D at Novavax, exercised stock options and sold shares on June 17, 2024, according to a Form 4 filing.

Director Margaret McGlynn reports the acquisition and disposal of Novavax stock and derivative securities.

Director Gregg H. Alton of Novavax Inc. reports the acquisition and disposal of common stock and derivative securities.

Director Richard Douglas reports acquisition and disposal of Novavax stock and derivative securities on June 12, 2024.

Director Rachel K. King reports the acquisition and disposal of Novavax Inc. stock and derivative securities.

Director David M. Mott reports acquisition and disposal of Novavax stock and derivative securities on June 12, 2024.

Director Richard J. Rodgers reported the acquisition and disposal of Novavax stock and derivative securities on June 12, 2024.